Four years of long-term data confirm the continued safety of the drug tildrakizumab in patients with psoriatic arthritis.
Christopher Ritchlin, MD, MPH
Advertisement
Articles by Christopher Ritchlin, MD, MPH
Advertisement
Latest Updated Articles
Sustained Safety of Tildrakizumab for Psoriatic ArthritisPublished: December 10th 2025 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
FDA to Accept Deidentified Real-World Evidence for Select Medical Device Applications
2
COVID-19 Vaccination in Pregnant Patients Reduces Hospitalization, Preterm Birth Across Variants
3
FDA Approves Fam-Trastuzumab Deruxtecan-Nxki for Metastatic HER2-Positive Breast Cancer
4
Orlowski Calls Linvoseltamab Results “the Best Single-Agent Data Ever in the History of Myeloma”
5
